Our findings emphasize the need to monitor and control CVD risk factors, such as elevated blood glucose, abnormal lipid levels, and changes in kidney function (ie, albuminuria, estimated glomerular filtration rate, and serum creatinine levels), in men with type 2 diabetes and PCa who are receiving GnRH agonists. The gene discussed is GNRH1; the disease is type 2 diabetes mellitus.